Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

7 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Eligibility Vascular Inflammation Acute Coronary Syndrome NCT00552188 - Eligibility Critera

- 28-07-15 - 1 formulario, 2 itemgroups, 23 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on vascular inflammation following 24 weeks of dosing. https://www.clinicaltrials.gov/ct2/show/NCT00552188

Excerpt PLATO Acute coronary Syndrome NCT00391872 - Section Event Forms

- 15-04-21 - 14 formularios, 6 itemgroups, 60 items, 1 idioma
Itemgroups: Death, Myocardial Infarction, Silent, Cardiac Ischaemic Event, Stroke/TIA, Bleeding Event, Arterial Thrombotic Event
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS. https://clinicaltrials.gov/ct2/show/NCT00391872

End of Treatment Visit

10 itemgroups 52 items

Section Investigational Products

5 itemgroups 4 items

Unscheduled Visit

6 itemgroups 40 items

Visit 4

5 itemgroups 39 items

Visit 2

6 itemgroups 37 items

Section Medication

2 itemgroups 2 items

Acute coronary syndrome (clinical) DSS 2013- Functional stress test cluster Metadata Online Registry (METeOR)

- 04-09-16 - 1 formulario, 2 itemgroups, 6 items, 1 idioma
Itemgroups: Functional stress test, Person
Health sector data set specifications from METeOR, Australia's repository for national metadata standards, developed by the Australian Institute of Health and Welfare (http://meteor.aihw.gov.au/content/index.phtml/itemId/345165) Acute coronary syndrome (clinical) DSS 2013-: The scope for the ACS data set specification is to collect data on the period between when a person with ACS symptoms was first referred to a hospital or directly presented at a hospital, and when a person leaves the hospital, either from the emergency department or is discharged from the hospital. Functional stress test cluster: A functional stress test evaluates arterial blood flow to the heart muscle during increased cardiac work through physical exercise or pharmacological methods. The functional stress test cluster collects information on the timing, characteristics and results of a functional stress test performed during the current hospital presentation. Metadata and Classifications Unit Australian Institute of Health and Welfare GPO Box 570 Canberra ACT 2601

Eligibility Ticagrelor Versus Clopidogrel Acute Coronary Syndrome NCT01294462 - Eligibility criteria

- 21-11-15 - 1 formulario, 2 itemgroups, 7 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion criteria
The purpose of the study is to assess the efficacy (prevention of vascular events) and safety (especially bleedings) of Ticagrelor (AZD6140) compared with Clopidogrel, both given on top of low dose aspirin, in Asian/Japanese patients with acute coronary syndrome and a planned percutaneous coronary intervention (PCI). https://clinicaltrials.gov/ct2/show/NCT01294462

Eligibility Rosuvastatin Acute Coronary Syndrome NCT01241903 - Eligibility Critera

- 21-11-15 - 1 formulario, 2 itemgroups, 20 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion criteria
The central hypothesis for this work is that platelet - leukocyte interactions play a critical role in the pathogenesis of acute ischemic events. The primary objective of the study is to determine if early, high-dose administration of the HMG-CoA reductase inhibitor rosuvastatin in the setting of acute coronary syndrome and percutaneous coronary intervention exerts beneficial vascular effects by reducing platelet - leukocyte interactions. https://clinicaltrials.gov/ct2/show/NCT01241903

Eligibility PLATO Acute Coronary Syndrome NCT00391872 - Eligibility Criteria

- 28-07-15 - 1 formulario, 2 itemgroups, 7 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS. https://clinicaltrials.gov/ct2/show/NCT00391872

Eligibility Acute Coronary Syndrome DRKS00000276 NCT01498731 DRKS00000276 - Eligibility Acute Coronary Syndrome NCT01498731 DRKS00000276

- 04-07-17 - 1 formulario, 2 itemgroups, 11 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Responsible Party: Martin Moeckel, Head Emergency Medicine, Charite University, Berlin, Germany ClinicalTrials.gov Identifier: NCT01498731 History of Changes Other Study ID Numbers: Charite-BiC-8 DRKS00000276 ( Other Identifier: German Clinical Trials Register ) U1111-1118-1665 ( Registry Identifier: International Clinical Trials Registry Platform ) Study First Received: October 25, 2011 Last Updated: June 4, 2013 Effect of the Biomarker Copeptin in Managing Patients With Suspected Acute Coronary Syndrome (ACS) (BiC-8) ODM derived from: https://clinicaltrials.gov/ct2/show/NCT01498731

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial